Loading…
← CockpitCompetitor Analysis › TWST Twist Bioscience Corp.Open in the cockpit ↗

Twist Bioscience Corp.TWSTCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Manufactures synthetic DNA on a silicon-chip platform, selling genes and DNA libraries to biotech, pharma and diagnostics researchers.

Momentum leader 92
Mkt cap
$7.93B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$327M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-42.2 pp
WACC 16.2%
Hurdle
n/a
no reverse DCF
Next earnings
72 days
29 Jan 2027
Close · USD$116.35
1D+3.9%
1W-5.1%
1M-18.5%
3M-14.7%
6M+116.8%
YTD+266.8%
1Y+339.7%
ATR %13.3%
Beta2.81
52w lowhigh47.0% off high

What Twist Bioscience does

Manufactures synthetic DNA on a silicon-chip platform, selling genes and DNA libraries to biotech, pharma and diagnostics researchers.

Sells synthetic DNA ordered online in many small orders, with revenue split across gene products, tools for preparing samples for sequencing, and antibody discovery services for drug developers. Orders come from a wide base of labs, so no single customer dominates, and most revenue is repeat consumables.

Products and services

  • Synthetic genes/DNA libraries
  • NGS (next-gen sequencing) tools
  • Biopharma (antibody discovery)
  • DNA data storage (early stage)

Customers

  • Biotech and pharma R&D labs
  • Academic/research institutions
  • Diagnostics companies

Where it sits in the supply chain

  • Healthcare/life sciences tools
  • Synthetic biology
  • Silicon-based DNA synthesis…

What could go right

  • Growing synthetic biology/gene-therapy research demand
  • NGS tools and biopharma segment growth

What could go wrong

  • Long path to profitability/cash burn
  • Customer R&D budget cyclicality

Moat: narrow (IP / patents, process know-how, scale). Proprietary silicon-based DNA synthesis technology enables lower-cost, higher-throughput gene manufacturing.

Headquarters: South San Francisco, California, US · Founded: 2013 · Employees: 1,080

Named competitors

Twist Bioscience at a glance

Size Twist Bioscience (TWST) is a United States Health Care company (Biotechnology) with a market value of $7.93B, the 884th largest of 3,085 United States companies the cockpit tracks. Shares closed at $116.35 on 18 Nov 2026.

Performance Over six months the shares gained 116.8%, against +23.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 22.0% over the last twelve months (peer median +26.0%); the operating margin is -28.8% (peer median 10.9%).

Valuation It trades at 16.2× enterprise value to sales against a peer median of 10.5× (7th most expensive of 17).

Capital Return on invested capital runs 42.2 points below its cost of capital (16.2% WACC).

Backlog Backlog (remaining performance obligations) was $21.6M at 30 Sep 2026, up 43% on a year earlier — 0.0 years of trailing revenue. Backlog detail →

Short interest Short interest is 14.9% of the free float (30 Oct 2026).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026TWST 198Peer median 120
Six months, rebased to 100: Twist Bioscience against the median of its 20 peers (local-currency closes).

Twist Bioscience financials

Reported figures in USD; fiscal year ends 2026-09-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$459M$459M$377M$313M$245M
Revenue growth—+22%+20%+28%—
Gross profit$241M$241M$191M$133M$89.7M
EBITDA-$106M-$106M-$111M-$144M-$178M
Net income-$130M-$130M-$77.7M-$209M-$205M
Free cash flow-$89.0M-$89.0M-$75.6M-$69.2M-$170M
Capital expenditure$54.5M$54.5M$28.0M$5.08M$27.8M
Total debt$95.0M$95.0M$75.6M$85.0M$94.1M

Quarterly statements and history in the cockpit →

Twist Bioscience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%TXGSMMT1548196170CGONAXSMIMVTPCVXKRYSKOD002422ARWRKYMRSRRKHALOCAIANTHEMTECHBMRN300122TWST6-month return →1-month return →
Up and to the right = strong over both horizons. Twist Bioscience is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×1,000×TXG1548196170CGONKRYS002422ARWRKYMR300122TWSTRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Twist Bioscience is the large dot.

Twist Bioscience competitors and peer comparison

Head to head with its named competitors (TWST vs DHR vs TMO vs AZTA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Twist Bioscience TWST$7.93B+117%+22%-29%16.2×n/a
Danaher DHR$161B+34%+6%21%7.1×20.8%
Thermo Fisher Scientific TMO$257B+53%+8%19%6.2×21.3%
Azenta AZTA$2.03B+162%+5%-2%2.8×38.0%
Agilent Technologies A$50.0B+56%+9%24%7.1×23.3%
Eurofins Scientific ERF.PA$16.4B+37%+3%12%2.7×12.9%

How Twist Bioscience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Twist Bioscience against its 20 peers (data as of 18 Nov 2026)
MeasureTWSTPeer medianRank in peer set
1-month return-18.5%-2.6%7th lowest of 21
6-month return+116.8%+23.0%4th highest of 21
Distance from 52-week high-47.0%-27.7%5th lowest of 21
Revenue growth (TTM)+22.0%+26.0%8th lowest of 16
Operating margin-28.8%10.9%6th lowest of 17
EV / Sales16.2×10.5×7th most expensive of 17
ROIC minus cost of capital-42.2 pp-0.5 pp4th lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%16.2×n/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%11.3×47.2%+16.6%
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%9.8×36.9%+19.8%
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%35.1×24.6%+38.5%
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%1,000.7×n/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%8.0×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%18.0×13.1%+26.0%
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%3.7×6.2%+2.3%
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%92.4×n/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%7.3×-0.3%+39.2%
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Bio-Techne TECHUnited States$11.4B+56%+1%21%9.2×31.6%+5.5%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%4.2×8.2%+12.0%
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%

Twist Bioscience backlog

Twist Bioscience reported $21.6M of remaining performance obligations at 30 Sep 2026, up 43% from a year earlier and down 1% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Twist Bioscience's main competitors?
Named competitors: Danaher (IDT) (DHR), Thermo Fisher Scientific (TMO), GenScript (private or unlisted), Azenta (AZTA), Agilent Technologies (A), Eurofins Scientific (ERF.PA). The cockpit's measured peer set (industry) also includes 10x Genomics (TXG), Summit Therapeutics (SMMT), Genscript Biotech (1548.HK), ALTEOGEN (196170.KS), CG Oncology (CGON), Axsome Therapeutics (AXSM).
Is Twist Bioscience expensive compared with its peers?
On ev / sales it trades at 16.2× against a peer median of 10.5×, 7th most expensive of 17 in its peer set.
How has Twist Bioscience stock performed?
Over six months to 18 Nov 2026 the shares returned +116.8% against +23.0% for the median peer; over one year +339.7%.
What is Twist Bioscience's backlog?
Twist Bioscience's remaining performance obligations (contracted revenue not yet recognised) were $21.6M at 30 Sep 2026, +43% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.